Business
Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
Continues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with p53-mutated non-small cell lung cancer (NSCLC)
About this update from Rein Therapeutics, Inc.
[{"type":"text","content":"Continues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapy Updated planned NSCLC study data readouts include interim results in 2Q22; topline full results in 4Q22 Reported preliminary data on ALRN-6924’s p21-mediated cell cycle arrest in healthy humans Confirmed biomarker-driven mechanism of actionCharacterized time to onset, magnitude and duration of cell cycle arrest, informing potential universal dose and schedule across distinct chemotherapy regimens $52.2 million cash and cash equivalents as of September 30, 2021, expected to fund operations into second half of 2023 BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today reported financial results and business highlights for the third quarter ended September 30, 2021. “In the third quarter, we continued our clinical progress, reporting final positive results from our chemoprotection proof-of-concept SCLC study and confirming ALRN-6924’s p21-mediated cell cycle arrest in our healthy volunteer study. We also reported healthy volunteer data on time to onset, magnitude and duration of ALRN-6924’s cell cycle arrest, which provides support for a universal dose and schedule across distinct chemotherapy regimens,” said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer at Aileron. “In the year ahead, we anticipate key data readouts from our NSCLC trial, as we continue to advance toward our vision to deliver selective chemoprotection to patients with p53-mutant cancers regardless of type of chemotherapy or cancer.” Dr. Aivado continued, “We recently presented preclinical data demonstrating cell cycle arrest in healthy tissue outside of the bone marrow – namely, epithelial mucosa cells in the GI tract. This is another important strategic building block, as a key characteristic of ALRN-6924’s differentiated profile is the potential to selectively protect multiple tissues and organs from chemotherapy-induced toxicities with a single medicine – representing a potential paradigm shift in the care of millions of cancer patients.” Despite the rise of immunotherapies and targeted therapies, chemotherapy ...